Using Precision Metabolomics™ To Evaluate A Drug's Ability To Deliver The Target Product Profile

Estimates vary, but the time and cost of bringing a drug successfully to market is over 12 years and greater than a billion dollars. These staggering estimates are driven by a >95% failure rate.

Most assessments of these high failure rates contend that, although the ultimate failure occurs in the clinic, that “clinical” failure is a more holistic problem that starts at discovery and extends all the way to the clinic. This eBook will focus on using metabolomics throughout the R&D process as an ally to improve the clinical success rate.

Biomarkers and deep insights into drug candidate response in both preclinical models and clinical trial subjects are a cornerstone for illuminating decisions across the drug development process. These insights and biomarkers also serve to feed and enrich powerfulmodel based drug discovery.

However, the models and insights will only be as strong as their input data – data that needs to be physiologically meaningful and comprehensive, as well as dynamic and quantitative. Metabolomics is a proven technology for delivering this type of data – it deeply assesses the molecular phenotype and provides the consequent signatures (biomarkers) that can be routinely monitored.

For companies seeking to ask and answer the “killer questions’ to illuminate a more productive path and circumvent a lot of inefficacy and risk, technologies that provide informative data and biomarkers – such as metabolomics – need to be embedded across the project life cycle rather than in a reactive or ad hoc way.

In this eBook, we will detail how metabolomics – by producing a comprehensive and meaningful assessment of the molecular phenotype – can enrich the biomarker and information armament to inform decisions across this continuum.